Enasidenib (AG-221, CC-90007, Idhifa®; Celgene Corporation, Summit, NJ, USA) is a selective, non-competitive inhibitor of IDH2 recently approved by the United States Food and Drug Administration (FDA) for relapsed/refractory mIDH2 AML. This evidence concerns the gene IDH2 and acute myeloid leukemia.